Gastrointestinal effects dominate the side effect profile
It was originally studied for gastrointestinal healing but researchers quickly identified potent effects on connective tissue, tendons, ligaments, and joints
Author contributions SH: Writing original draft, Writing review & editing
Survodutide (BI 456906) is another glucagon/GLP-1 receptor dual agonist with a recent phase II randomized, double-blind study showing reduced glycosylated hemoglobin (HbA1c) levels and bodyweight after 16 weeks treatment in participants with T2DM
Before considering it as a treatment option, its important to understand the science behind it, how it compares to other therapies, and the significant safety questions that remain unanswered
Understanding these mechanisms provides insight into how this peptide produces its body composition effects